Sequoia Financial Advisors LLC Grows Stock Position in Boston Scientific Co. (NYSE:BSX)

Sequoia Financial Advisors LLC increased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 14.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,271 shares of the medical equipment provider's stock after buying an additional 3,879 shares during the period. Sequoia Financial Advisors LLC's holdings in Boston Scientific were worth $2,704,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BSX. Adero Partners LLC increased its stake in Boston Scientific by 3.3% during the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock valued at $334,000 after purchasing an additional 120 shares in the last quarter. Grove Bank & Trust lifted its holdings in Boston Scientific by 4.4% in the fourth quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after acquiring an additional 122 shares during the period. PFG Investments LLC boosted its holdings in shares of Boston Scientific by 1.6% in the fourth quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock worth $725,000 after buying an additional 125 shares during the last quarter. Stonegate Investment Group LLC grew its position in shares of Boston Scientific by 1.6% during the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider's stock valued at $699,000 after acquiring an additional 126 shares during the period. Finally, MinichMacGregor Wealth Management LLC grew its holdings in Boston Scientific by 2.3% during the fourth quarter. MinichMacGregor Wealth Management LLC now owns 5,689 shares of the medical equipment provider's stock valued at $508,000 after purchasing an additional 130 shares during the period. Institutional investors own 89.07% of the company's stock.

Remove Ads

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded up $1.66 on Monday, reaching $98.82. 2,145,906 shares of the stock were exchanged, compared to its average volume of 5,730,662. The business has a 50 day moving average price of $101.05 and a two-hundred day moving average price of $91.84. The firm has a market capitalization of $145.83 billion, a price-to-earnings ratio of 79.05, a PEG ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a twelve month low of $66.16 and a twelve month high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the completion of the sale, the executive vice president now directly owns 25,443 shares in the company, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 137,302 shares of company stock valued at $14,319,269. Corporate insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on BSX shares. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research note on Friday, January 10th. Raymond James upped their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. UBS Group increased their price objective on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Finally, Stifel Nicolaus lifted their target price on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.